Imbruvica
E51059
Bruton tyrosine kinase inhibitor
pharmaceutical drug
small molecule inhibitor
targeted cancer therapy
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
All labels observed (2)
How this entity was disambiguated
This entity first appeared as the object of triple T391440 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Imbruvica Context triple: [Johnson & Johnson, notableProduct, Imbruvica]
-
A.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
E.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Imbruvica Target entity description: Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
A.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
E.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
- F. None of above. chosen
Statements (53)
| Predicate | Object |
|---|---|
| instanceOf |
Bruton tyrosine kinase inhibitor
ⓘ
pharmaceutical drug ⓘ small molecule inhibitor ⓘ targeted cancer therapy ⓘ |
| hasAdministrationNote |
should be swallowed whole with water
ⓘ
should be taken at approximately the same time each day ⓘ |
| hasATCCode | L01EL01 ⓘ |
| hasBioavailability | variable and food-dependent ⓘ |
| hasBlackBoxWarningUS |
cardiac arrhythmias
ⓘ
embryo-fetal toxicity ⓘ hemorrhage ⓘ infections ⓘ second primary malignancies ⓘ |
| hasChemicalClass | diaminopyrimidine derivative ⓘ |
| hasCommonAdverseEffect |
bruising
ⓘ
diarrhea ⓘ fatigue ⓘ nausea ⓘ rash ⓘ |
| hasDosageForm |
capsule
ⓘ
tablet ⓘ |
| hasEliminationHalfLife | 4 to 6 hours ⓘ |
| hasGenericName | ibrutinib ⓘ |
| hasIndicationRegion |
European Union
ⓘ
United States of America ⓘ
surface form:
United States
|
| hasInitialApprovalYearUS | 2013 ⓘ |
| hasINN | ibrutinib ⓘ |
| hasLegalStatusEU | prescription only ⓘ |
| hasLegalStatusUS | prescription only ⓘ |
| hasMechanismOfAction | irreversible inhibition of Bruton tyrosine kinase ⓘ |
| hasPregnancyCategoryUS | D ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSeriousAdverseEffect |
atrial fibrillation
ⓘ
bleeding ⓘ hypertension ⓘ infections ⓘ |
| isAdministered | once daily ⓘ |
| isContraindicatedWith | strong CYP3A4 inhibitors ⓘ |
| isExcretedVia | feces ⓘ |
| isMarketedBy |
AbbVie
ⓘ
Janssen Biotech ⓘ |
| isMetabolizedBy | CYP3A4 ⓘ |
| isUsedFor |
Waldenstrom macroglobulinemia
ⓘ
chronic graft-versus-host disease ⓘ chronic lymphocytic leukemia ⓘ mantle cell lymphoma ⓘ marginal zone lymphoma ⓘ previously untreated chronic lymphocytic leukemia ⓘ relapsed mantle cell lymphoma ⓘ relapsed or refractory chronic lymphocytic leukemia ⓘ small lymphocytic lymphoma ⓘ |
| targets | Bruton tyrosine kinase ⓘ |
| wasApprovedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Imbruvica Description of subject: Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
ibrutinib